FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
NEW YORK, March 16, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- Oppenheimer 27th Annual Healthcare Conference on March 21, 2017 at 3:55 p.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
